Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH1 Mutation”

100 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 100 results

Early research (Phase 1)Ended earlyNCT05814536
What this trial is testing

IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor

Who this might be right for
Cholangiocarcinoma With IDH1 MutationSolid Tumors With IDH1 Mutation
AnHeart Therapeutics Inc. 9
Testing effectiveness (Phase 2)Looking for participantsNCT06717958
What this trial is testing

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

Who this might be right for
AMLMDS
Technische Universität Dresden 76
Large-scale testing (Phase 3)Active Not RecruitingNCT03839771
What this trial is testing

Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2
Stichting Hemato-Oncologie voor Volwassenen Nederland 968
Testing effectiveness (Phase 2)Looking for participantsNCT06611839
What this trial is testing

Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

Who this might be right for
AMLIDH1 MutationTreatment
Institute of Hematology & Blood Diseases Hospital, China 29
Large-scale testing (Phase 3)Looking for participantsNCT06387069
What this trial is testing

Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Hutchmed 316
Testing effectiveness (Phase 2)Active Not RecruitingNCT02677922
What this trial is testing

Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Who this might be right for
Leukemia, Myeloid, Acute
Celgene 130
Not applicableApproved For MarketingNCT05592743
What this trial is testing

Vorasidenib Expanded Access Program

Who this might be right for
GliomaRecurrenceDisease Attributes+8 more
Servier
Testing effectiveness (Phase 2)WithdrawnNCT04044209
What this trial is testing

The IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Yale University
Testing effectiveness (Phase 2)Active Not RecruitingNCT03503409
What this trial is testing

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Groupe Francophone des Myelodysplasies 68
Large-scale testing (Phase 3)Active Not RecruitingNCT04576117
What this trial is testing

Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Who this might be right for
Recurrent Low Grade AstrocytomaRecurrent WHO Grade 2 GliomaRefractory Low Grade Astrocytoma+2 more
National Cancer Institute (NCI) 300
Testing effectiveness (Phase 2)Ended earlyNCT05921760
What this trial is testing

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

Who this might be right for
IDH1-mutant Cholangiocarcinoma
Servier Bio-Innovation LLC 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT06478212
What this trial is testing

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

Who this might be right for
IDH1-mutant GliomaIDH2-mutant Glioma
Institut de Recherches Internationales Servier 51
Large-scale testing (Phase 3)Active Not RecruitingNCT06780930
What this trial is testing

Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

Who this might be right for
Residual or Recurrent Grade 2 IDH Mutant Glioma
Servier 57
Large-scale testing (Phase 3)Active Not RecruitingNCT04164901
What this trial is testing

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Who this might be right for
Grade 2 GliomaResidual GliomaRecurrent Glioma
Institut de Recherches Internationales Servier 331
Testing effectiveness (Phase 2)WithdrawnNCT02987010
What this trial is testing

Phase 2 Study of IDH305 in Low Grade Gliomas

Who this might be right for
Glioma
University of Texas Southwestern Medical Center
Not applicableUnknownNCT02333513
What this trial is testing

Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Who this might be right for
Recurrent High-grade Glioma
Hebei Yanda Hospital 100
Early research (Phase 1)Looking for participantsNCT06291987
What this trial is testing

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

Who this might be right for
Myeloproliferative Neoplasms
University of Chicago 18
Testing effectiveness (Phase 2)Looking for participantsNCT06501625
What this trial is testing

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Who this might be right for
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Institut de Recherches Internationales Servier 52
Very early researchStudy completedNCT05577416
What this trial is testing

AB-218 in Patients With IDH1 Mutated Low Grade Glioma

Who this might be right for
Glioma
Melbourne Health 14
Early research (Phase 1)Looking for participantsNCT02074839
What this trial is testing

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Who this might be right for
Relapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AMLOther IDH1-mutated Positive Hematologic Malignancies+1 more
Institut de Recherches Internationales Servier 291
Load More Results